← All trials
NCT04009525
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2019
- Primary completion
- May 31, 2022
- Completion date
- May 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 800
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hacettepe UniversityLead sponsor
- Peking UniversityCollaborator
- Guizhou Medical UniversityCollaborator
- Hacettepe UniversityOverall official - principal investigator
- Hacettepe UniversityReponsible party - principal investigator
- Jiao Tong UniversityCollaborator
- The First People's Hospital of Yunan ProvinceCollaborator
- Guangxi Medical UniversityCollaborator
- Hainan People's HospitalCollaborator
- People's Liberation Army of ChinaCollaborator
- Liuzhou General HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.